Literature DB >> 13756616

Chronic renal failure. Its effect on calcium, phosphorus and osseous metabolism unified approach.

C R KLEEMAN, D BERNSTEIN.   

Abstract

The renal osteodystrophies represent the metabolic consequences of (1) vitamin D resistance, (2) secondary hyperplasia of the parathyroids, and (3) the changes in serum PO(4)= and Ca++ secondary to the renal insufficiency per se. The osseous lesion in any given patient with chronic renal failure may be osteitis fibrosa, rickets (osteomalacia), calcium deficiency osteoporosis or any combination of these. The concentration of Ca++ and PO(4)= in the serum is determined by the degree of renal failure and the skeletal response to parathyroid hormone.

Entities:  

Keywords:  CALCIUM/metabolism; DIURESIS/physiology; KIDNEY DISEASES/complications; PHOSPHORUS/metabolism; RICKETS, RENAL/etiology

Mesh:

Substances:

Year:  1961        PMID: 13756616      PMCID: PMC1574426     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  5 in total

1.  Elective subtotal parathyroidectomy for renal hyperparathyroidism.

Authors:  S W STANBURY; G A LUMB; W F NICHOLSON
Journal:  Lancet       Date:  1960-04-09       Impact factor: 79.321

2.  Parathyroid hormone. Nature and mechanism of action.

Authors:  H RASMUSSEN
Journal:  Am J Med       Date:  1961-01       Impact factor: 4.965

3.  Azotaemic renal osteodystrophy.

Authors:  S W STANBURY
Journal:  Br Med Bull       Date:  1957-01       Impact factor: 4.291

4.  Phosphorus excretion in renal failure.

Authors:  R GOLDMAN; S H BASSETT
Journal:  J Clin Invest       Date:  1954-12       Impact factor: 14.808

5.  Vitamin D and citrate metabolism; effect of vitamin D in rats fed diets adequate in both calcium and phosphorus.

Authors:  H C HARRISON; H E HARRISON; E A PARK
Journal:  Am J Physiol       Date:  1958-02
  5 in total
  4 in total

1.  Vitamin D and Atherosclerotic Cardiovascular Disease.

Authors:  Thomas Hiemstra; Kenneth Lim; Ravi Thadhani; JoAnn E Manson
Journal:  J Clin Endocrinol Metab       Date:  2019-04-04       Impact factor: 5.958

2.  Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism.

Authors:  Takashi Shigematsu; Masafumi Fukagawa; Keitaro Yokoyama; Takashi Akiba; Akifumi Fujii; Motoi Odani; Tadao Akizawa
Journal:  Clin Exp Nephrol       Date:  2017-08-23       Impact factor: 2.801

3.  Divalent ion metabolism and osteodystrophy in chronic renal failure.

Authors:  C R Kleeman; O Better; S G Massry; M H Maxwell
Journal:  Yale J Biol Med       Date:  1967-08-01

4.  Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism.

Authors:  Takashi Shigematsu; Masafumi Fukagawa; Keitaro Yokoyama; Takashi Akiba; Akifumi Fujii; Atsushi Shinoda; Tadao Akizawa
Journal:  Nephrology (Carlton)       Date:  2019-12-27       Impact factor: 2.506

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.